Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Qilu Pharma Starts China Bridging Trial for Bladder Cancer Drug

publication date: Jul 21, 2021

Jilin Qilu Pharmaceutical has enrolled the first patient in a China bridging trial of Vicineum in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). One year ago, Qilu in-licensed China rights to the candidate from Boston's Sesen Bio in a deal worth $38 million. The start of the trial triggered a $3 million milestone payment. Sesen develops targeted fusion protein therapeutics for cancer. Qilu expects to submit a China market application for Vicineum in 2022; a decision on Sesen's application for US marketing approval is due in August. More details....

Stock Symbol: (NSDQ: SESN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.